Gregory B Little - President & CEO

Mr. Little launched fOCUS Pharmaceuticals in January 2002 and formed the company into a LLC in the state of California in June of 2002. He has a wide range of business experience in the pharmaceutical industry, totaling 20 years, with companies like Pfizer Pharmaceuticals, ICN Pharmaceuticals and R&D Laboratories. During his career be began as a sales representative with Pfizer, later joined ICN working up to a senior level of responsibility as Director of Sales, Pharmaceutical Division, North America, and was a senior management member of R&D Laboratories (acquired by Watson Pharmaceuticals). He was involved with R&D’s first FDA approved product, Ferrlecit®, served as a member of the Schein Pharmaceutical and R&D Laboratories joint marketing committee for successful commercialization of Ferrlecit® and chairman of Schein Pharmaceutical's clinical development. He has successfully integrated new acquisitions and launched new products during his career. During his time at ICN the company was ranked number one by the Wall Street Journal for total shareholder return (53.4%) and experienced record growth in its North American business. Little has experience with large and start-up pharmaceutical companies. fOCUS Pharmaceuticals and fOCUS Biotech were formed to research and develop existing and new therapeutic compounds to treat a variety of diseases and conditions of the skin.